and there's the rub ....
Analysts from Cantor Fitzgerald believed Mesoblast had sufficient data to allay the FDA’s concerns.
“MESO has potency assays and experience from clinical trials to correlate this potency to measurable clinical outcomes,” the analysts said in a note to investors.
“We think MESO will be able to address the concerns that were raised in the briefing materials. The topics of discussion were already anticipated by the company, and MESO has been preparing for the AdCom (advisory committee).”
Tip: 3.84 close
- Forums
- ASX - By Stock
- MSB
- MSB Trading - Aug 2020 on
MSB Trading - Aug 2020 on, page-924
-
- There are more pages in this discussion • 1,461 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.16 |
Change
-0.005(0.43%) |
Mkt cap ! $1.330B |
Open | High | Low | Value | Volume |
$1.15 | $1.17 | $1.15 | $483.9K | 417.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 33623 | $1.16 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.16 | 689 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 59542 | 1.165 |
8 | 95084 | 1.160 |
7 | 64755 | 1.155 |
8 | 143232 | 1.150 |
4 | 142497 | 1.145 |
Price($) | Vol. | No. |
---|---|---|
1.170 | 2305 | 1 |
1.175 | 82673 | 6 |
1.180 | 155709 | 10 |
1.185 | 37232 | 4 |
1.190 | 41238 | 7 |
Last trade - 10.18am 16/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online